Severe Hemophilia A
32
4
7
17
Key Insights
Highlights
Success Rate
85% trial completion
Published Results
15 trials with published results (47%)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
9.4%
3 terminated out of 32 trials
85.0%
-1.5% vs benchmark
59%
19 trials in Phase 3/4
88%
15 of 17 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 17 completed trials
Clinical Trials (32)
To Evaluate the Safety and Efficacy of GS1191-0445 Injection in the Treatment of Severe Hemophilia A
A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Participants From Birth to 12 Months of Age With Hemophilia A Without Inhibitors
Post Approval Observational Study to Learn More About How Safe Octocog Alfa is and How Well it Works in Patients With Severe Hemophilia A in India
A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A.
Palliative Care Needs of Children With Rare Diseases and Their Families
Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study
Safety and Pharmacokinetics of Subcutaneous Injection of OCTA101 in Adult Patients With Severe Hemophilia A
Safety Study of Alphanate in Previously Treated Patients With Severe Hemophilia A
Study of Efficacy and Safety of FRSW107 in Pediatric Patients With Severe Hemophilia A
Bone Microarchitecture in Men With Hemophilia
Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein
rFVIII-Fc (Produced by AryoGen Pharmed Co.) Pharmacokinetic Study
A Study to Evaluate the Pharmacokinetics，Safety and Tolerability of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection
Dynamics of the Anti-factor VIII Antibody Signature During Treatment With Emicizumab
A Study of Repeat Dosing of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection
An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A
Rescue Immunotolerance Study in Induction of Immune Tolerance (ITI)-Experienced Patients (RES.I.S.T. Experienced)
Study to Investigate Immunogenicity, Efficacy and Safety of Treatment With Human-cl rhFVIII
Human Cell Line-derived Recombinant Factor VIII (Human-cl-rhFVIII) in Previously Untreated Patients